Takano, Shigetsugu <br/><br/>
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.  [electronic resource] 

 -  Annals of surgical oncology  Nov 2008 
 - 3157-68 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1534-4681 
<br/><br/><label>Standard No.: </label>10.1245/s10434-008-0061-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Annexin A2--genetics<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Blotting, Western<br/>Carcinoma, Adenosquamous--drug therapy<br/>Carcinoma, Pancreatic Ductal--drug therapy<br/>Cell Survival--drug effects<br/>Chemotherapy, Adjuvant<br/>Deoxycytidine--analogs & derivatives<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Immunoenzyme Techniques<br/>Male<br/>Middle Aged<br/>Neoplasm Invasiveness<br/>Neoplasm Recurrence, Local--diagnosis<br/>Pancreatic Neoplasms--drug therapy<br/>Prognosis<br/>RNA, Messenger--genetics<br/>RNA, Small Interfering--pharmacology<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Survival Rate<br/>Tumor Cells, Cultured<br/>Gemcitabine